Antithrombotic management in patients undergoing cardiac implantable electronic device implantation
DOI:
https://doi.org/10.6016/ZdravVestn.3402Keywords:
cardiac pacemaker, pocket hematoma, perioperative anticoagulation, device complications, antiplateletsAbstract
Cardiac implantable electronic devices (CIEDs) are an established treatment option for arrhythmias, sudden cardiac death prevention, and heart failure. Approximately 1000 devices are implanted per million inhabitants in European countries each year. However, the main concern in patients with an indication for CIED implantation is frequently associated with comorbidities requiring antithrombotic medications. The invasive device implantation procedure represents a bleeding risk ranging from pocket hematoma to cardiac tamponade. On the other hand, temporary interruption of antithrombotic therapy increases the risk for thromboembolic events. Implanting CIEDs in patients on antithrombotic medications incites several clinical dilemmas of balancing thromboembolic risk against bleeding risk, as complications are associated with higher mortality rates in both aspects. The most common bleeding complication is pocket haematoma formation, which is associated with a prolonged hospital stay, higher cost, higher risk of pocket infection, and thus higher morbidity and mortality. Studies have shown that the heparin bridging strategy in patients on oral anticoagulants imposes a greater risk for pocket haematoma formation and no benefit in reducing thromboembolic events. Most procedures of CIED implantation can be performed safely with uninterrupted oral anticoagulants. Dual antiplatelet therapy increases the risk of pocket haematoma and should be avoided whenever possible.
Downloads
References
1. Raatikainen MJ, Arnar DO, Merkely B, Nielsen JC, Hindricks G, Heidbuchel H, et al. A Decade of Information on the Use of Cardiac Implantable Electronic Devices and Interventional Electrophysiological Procedures in the European Society of Cardiology Countries: 2017 Report from the European Heart Rhythm Association. Europace. 2017;19:ii1-90.
DOI: 10.1093/europace/eux258
PMID: 28903470
2. DeSimone CV, DeSimone DC, Cha YM. Contemporary Management of Antiplatelet and Anticoagulation for Cardiac Implantable Device Procedures. Circ Arrhythm Electrophysiol. 2019;12(10):e007863.
DOI: 10.1161/CIRCEP.119.007863
PMID: 31610719
3. Stewart MH, Morin DP. Management of Perioperative Anticoagulation for Device Implantation. Card Electrophysiol Clin. 2018;10(1):99-109.
DOI: 10.1016/j.ccep.2017.11.008
PMID: 29428146
4. Zacà V, Marcucci R, Parodi G, Limbruno U, Notarstefano P, Pieragnoli P, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17(6):840-54.
DOI: 10.1093/europace/euu357
PMID: 25712980
5. Raunsø J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM, et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J. 2012;33(15):1886-92.
DOI: 10.1093/eurheartj/ehr454
PMID: 22199117
6. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427-520.
DOI: 10.1093/eurheartj/ehab364
PMID: 34455430
7. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008;168(1):63-9.
DOI: 10.1001/archinternmed.2007.23
PMID: 18195197
8. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol. 2006;47(12):2493-7.
DOI: 10.1016/j.jacc.2006.02.049
PMID: 16781379
9. Zacà V, Marcucci R, Parodi G, Limbruno U, Notarstefano P, Pieragnoli P, et al. Management of antithrombotic therapy in patients undergoing electrophysiological device surgery. Europace. 2015;17(6):840-54.
DOI: 10.1093/europace/euu357
PMID: 25712980
10. Essebag V, Verma A, Healey JS, Krahn AD, Kalfon E, Coutu B, et al.; BRUISE CONTROL Investigators. Clinically significant pocket hematoma increases long-term risk of device infection: BRUISE CONTROL INFECTION study. J Am Coll Cardiol. 2016;67(11):1300-8.
DOI: 10.1016/j.jacc.2016.01.009
PMID: 26988951
11. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e326S-50S.
DOI: 10.1378/chest.11-2298
PMID: 22315266
12. Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL, Ortel TL, Saxonhouse SJ, et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017;69(7):871-98.
DOI: 10.1016/j.jacc.2016.11.024
PMID: 28081965
13. Vene N, Mavri A, Gubenšek M, Tratar G, Vižintin Cuderman T, Pohar Perme M, et al. PLoS One. 2016;11(6):e0156943.
DOI: 10.1371/journal.pone.01569434
PMID: 27280704
14. Mavri A, Blinc A, Peternel P. Antikoagulacijsko zdravljenje. 1. izd. Ljubljana: Slovensko zdravniško društvo, Sekcija za antikoagulacijsko zdravljenje in preprečevanje trombemboličnih bolezni pri Združenju za žilne bolezni; 2017.
15. Deharo JC, Sciaraffia E, Leclercq C, Amara W, Doering M, Bongiorni MG, et al.; Coordinated by the Scientific Initiatives Committee of the European Heart Rhythm Association. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). Europace. 2016;18(5):778-84.
DOI: 10.1093/europace/euw127
PMID: 27226497
16. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al.; BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368(22):2084-93.
DOI: 10.1056/NEJMoa1302946
PMID: 23659733
17. Sant’anna RT, Leiria TL, Nascimento T, Sant’anna JR, Kalil RA, Lima GG, et al. Meta-analysis of continuous oral anticoagulants versus heparin bridging in patients undergoing CIED surgery: reappraisal after the BRUISE study. Pacing Clin Electrophysiol. 2015;38(4):417-23.
DOI: 10.1111/pace.12557
PMID: 25546244
18. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al.; BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med. 2015;373(9):823-33.
DOI: 10.1056/NEJMoa1501035
PMID: 26095867
19. Proietti R, Porto I, Levi M, Leo A, Russo V, Kalfon E, et al. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. Eur Rev Med Pharmacol Sci. 2015;19(8):1461-79.
PMID: 25967723
20. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
DOI: 10.1093/eurheartj/ehaa612
PMID: 32860505
21. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al.; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021;23(10):1612-76.
DOI: 10.1093/europace/euab065
PMID: 33895845
22. Essebag V, Proietti R, Birnie DH, Wang J, Douketis J, Coutu B, et al. Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace. 2017;19(10):1630-6.
DOI: 10.1093/europace/euw409
PMID: 28339794
23. Leef GC, Hellkamp AS, Patel MR, Becker RC, Berkowitz SD, Breithardt G, et al. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. J Am Heart Assoc. 2017;6(6):e004663.
DOI: 10.1161/JAHA.116.004663
PMID: 28615214
24. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92.
DOI: 10.1056/NEJMoa1107039
PMID: 21870978
25. Birnie DH, Healey JS, Wells GA, Ayala-Paredes F, Coutu B, Sumner GL, et al. Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). Eur Heart J. 2018;39(44):3973-9.
DOI: 10.1093/eurheartj/ehy413
PMID: 30462279
26. Kutinsky IB, Jarandilla R, Jewett M, Haines DE. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol. 2010;3(4):312-8.
DOI: 10.1161/CIRCEP.109.917625
PMID: 20558847
27. Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, et al. Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. J Am Coll Cardiol. 2010;55(21):2376-82.
DOI: 10.1016/j.jacc.2009.12.056
PMID: 20488310
28. Essebag V, Healey JS, Joza J, Nery PB, Kalfon E, Leiria TL, et al. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: combined Analysis of BRUISE CONTROL 1 and 2. Circ Arrhythm Electrophysiol. 2019;12(10):e007545.
DOI: 10.1161/CIRCEP.119.007545
PMID: 31610718
29. Burri H, Starck C, Auricchio A, Biffi M, Burri M, D’Avila A, et al. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and t. EP Eur. 2021;23(7):983-1008.
PMID: 33878762
30. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al.; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-93.
DOI: 10.1093/eurheartj/ehy136
PMID: 29562325
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
